免疫抑制剂在风湿病相关复发性流产中的应用

doi:10.6040/j.issn.1671-7554.0.2021.0935

摘要/Abstract

摘要： 复发性流产(RSA)的主要病因之一为合并风湿免疫病。近年来,免疫抑制剂在RSA合并风湿免疫病患者的治疗方案中逐渐占据主要地位,其治疗效果也普遍得到认可。由于RSA合并风湿免疫病涉及到多个学科领域,目前对于免疫抑制剂的适应证及用法用量亟待进一步规范。论文结合近年的临床指南和科学研究进展,从RSA定义、风湿病与RSA相关性、免疫抑制剂的使用等方面,对国内外现有文献进行述评,提高读者对于相关疾病及药物的认识,为临床医师在实践中做出合理决策提供参考。

关键词: 免疫抑制剂, 复发性流产, 风湿病, 类风湿关节炎, 系统性红斑狼疮, 结缔组织病

Abstract: One of the main causes of recurrent spontaneous abortion(RSA)is the combination of rheumatologic diseases. In recent years, immunosuppressive agents have gradually taken the main role in the treatment of patients with RSA combined with rheumatologic diseases, and their therapeutic effects are generally recognized. Since RSA combined with rheumatic immune disease involves several disciplines, the indications and dosage of immunosuppressants need to be further standardized. In this paper, we review the existing domestic and international literature in terms of the definition of RSA, the correlation between rheumatic diseases and RSA, and the use of immunosuppressive drugs, in order to improve the readers understanding of related diseases and drugs, and to provide reference for clinicians to make rational decisions in practice.

Key words: Immunosuppressants, Recurrent spontaneous abortion, Rheumatic diseases, Rheumatoid arthritis, Systemic lupus erythematosus, Connective tissue disease

中图分类号:

R593.2

国云飞,舒强. 免疫抑制剂在风湿病相关复发性流产中的应用[J]. 山东大学学报 (医学版), 2021, 59(8): 38-43.

GUO Yunfei, SHU Qiang. Role of immunosuppressants in rheumatic disease-associated recurrent spontaneous abortion[J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 38-43.

参考文献

[1] Eudy AM, Siega-Riz AM, Engel SM, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus[J]. Ann Rheum Dis, 2018, 77(6): 855-860.
[2] Sugawara E, Kato M, Fujieda Y, et al. Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan[J]. Lupus, 2019, 28(12): 1407-1416.
[3] 复发性流产合并风湿免疫病免疫抑制剂应用中国专家共识编写组. 复发性流产合并风湿免疫病免疫抑制剂应用中国专家共识[J]. 中华生殖与避孕杂志, 2020, 40(7): 527-534.
[4] 自然流产诊治中国专家共识编写组.自然流产诊治中国专家共识(2020年版)[J]. 中国实用妇科与产科杂志, 2020, 36(11): 1082-1090.
[5] Chen Y, Wu Q, Wei J, et al. Effects of aspirin, vitamin D3, and progesterone on pregnancy outcomes in an autoimmune recurrent spontaneous abortion model[J]. Braz J Med Biol Res, 2021, 54(9): e9570. doi: 10.1590/1414-431X2020e9570.
[6] Ceccarelli F, Pirone C, Perricone C, et al. Pregnancy outcome in systemic lupus erythematosus patients: a monocentric cohort analysis[J]. Rheumatology(Oxford), 2021, 60(4): 1747-1754.
[7] Hiramatsu Y, Isoda K, Kotani T, et al. Pre-pregnancy serum complement C3 level is a predictor of preterm birth for pregnancies with systemic lupus erythematosus[J]. Arthritis Res Ther, 2021, 23(1): 140. doi: 10.1186/s13075-021-02522-x.
[8] Zhang S, Wu Z, Zhang W, et al. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome[J]. Clin Chim Acta, 2019, 495: 205-209. doi: 10.1016/j.cca.2019.04.065.
[9] Nalli C, Lini D, Andreoli L, et al. Low preconception complement levels are associated with adverse pregnancy outcomes in a multicenter study of 260 pregnancies in 197 women with antiphospholipid syndrome or carriers of antiphospholipid antibodies[J]. Biomedicines, 2021, 9(6): 671. doi: 10.3390/biomedicines9060671.
[10] Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome[J]. J Thromb Haemost, 2021, 19(4): 892-908.
[11] Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases[J]. Arthritis Rheumatol, 2020, 72(4): 529-556.
[12] Bröms G, Kieler H, Ekbom A, et al. Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden[J]. Pharmacoepidemiol Drug Saf, 2020, 29(3): 316-327.
[13] Elliott B, Spence AR, Czuzoj-Shulman N, et al. Effect of Sjögrens syndrome on maternal and neonatal outcomes of pregnancy[J]. J Perinat Med, 2019, 47(6): 637-642.
[14] Spinillo A, Beneventi F, Ramoni V, et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy[J]. Annals of the Rheumatic Diseases, 2012, 71(6): 918-923.
[15] Zucchi D, Tani C, Monacci F, et al. Pregnancy and undifferentiated connective tissue disease: outcome and risk of flare in 100 pregnancies[J]. Rheumatology(Oxford), 2020, 59(6): 1335-1339.
[16] de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage[J]. Br J Clin Pharmacol, 2020, 86(1): 39-49.
[17] Duan J, Ma D, Wen X, et al. Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: a meta-analysis[J]. Lupus, 2021, 30(7): 1163-1174.
[18] Yang S, Ni R, Lu Y, et al. A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses(ILIFE)trial[J]. Trials, 2020, 21(1): 771. doi: 10.1186/s13063-020-04716-1.
[19] Dong Y, Lu Y, Xia Y, et al. Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis[J]. J Matern Fetal Neonatal Med, 2021: 1-9. doi: 10.1080/14767058.2021.1943656.
[20] Ou H, Yu Q. Efficacy of aspirin, prednisone, and multivitamin triple therapy in treating unexplained recurrent spontaneous abortion: a cohort study[J]. Int J Gynaecol Obstet, 2020, 148(1): 21-26.
[21] Ince-Askan H, van den Akker ELT, de Rijke YB, et al. Associations between antenatal prednisone exposure and long-term cortisol and cortisone concentrations in children born to women with rheumatoid arthritis: results from a nationwide prospective cohort study[J]. RMD Open, 2019, 5(1): e000852. doi: 10.1136/rmdopen-2018-000852.
[22] De Cock D, Brants L, Soenen I, et al. A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis[J]. Semin Arthritis Rheum, 2020, 50(5): 873-878.
[23] Huang W, Lu W, Li Q, et al. Effects of cyclosporine A on proliferation, invasion and migration of HTR-8/SVneo human extravillous trophoblasts[J]. Biochem Biophys Res Commun, 2020, 533(4): 645-650.
[24] Sharma UR, Rathnakaran AN, Raj BPP, et al. The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy[J]. Inflammopharmacology, 2021, 29(4): 987-1000.
[25] Balbi GGM, Domingues V, Balbi GGM, et al. Use of synthetic and biologic DMARDs during pregnancy[J]. Expert Rev Clin Immunol, 2019, 15(1): 27-39.
[26] Ponticelli C, Moroni G. Fetal toxicity of immunosuppressive drugs in pregnancy[J]. J Clin Med, 2018, 7(12): 552. doi: 10.3390/jcm7120552.
[27] Yang X, Meng T. Is there a role of intravenous immunoglobulin in immunologic recurrent pregnancy loss?[J]. J Immunol Res, 2020, 2020: 6672865. doi: 10.1155/2020/6672865.
[28] Urban ML, Bettiol A, Serena C, et al. Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: a case series and systematic review of literature[J]. Autoimmun Rev, 2020, 19(9): 102620. doi: 10.1016/j.autrev.2020.102620.
[29] Prieto-Peña D, Calderón-Goercke M, Adán A, et al. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy[J]. Clin Exp Rheumatol, 2021, 39(1): 105-114.
[30] Perrotta K, Kiernan E, Bandoli G, et al. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series[J]. Rheumatol Adv Pract, 2021, 5(1): rkaa074. doi: 10.1093/rap/rkaa074.
[31] Saito J, Yakuwa N, Kaneko K, et al. Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum[J]. Rheumatology(Oxford), 2019, 58(8): 1505-1507.
[32] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745.
[33] Akhlaghi M, Kianersi F, Radmehr H, et al. Evaluation of optical coherence tomography angiography parameters in patients treated with Hydroxychloroquine[J]. BMC Ophthalmol, 2021, 21(1): 209. doi: 10.1186/s12886-021-01977-5.

相关文章 15

[1]	段盈竹,董波,于睿. 内在情感与类风湿关节炎患者冠状动脉粥样硬化风险关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2026, 64(4): 63-71.
[2]	万文静,高姗姗. 低分子肝素在生殖领域的应用[J]. 山东大学学报 (医学版), 2025, 63(6): 117-124.
[3]	宋慧梳,孙志坚,张邱婷,弭雪,张妮,王志仑,尹哲,郝学喜,王迎雪. MiR-125a-3p对类风湿关节炎滑膜成纤维细胞增殖的影响[J]. 山东大学学报 (医学版), 2025, 63(12): 74-78.
[4]	康随芳,王迎雪,张琪晨,王志仑,尹哲,肖娟,陈国玲. 系统性红斑狼疮患者睑板腺形态和功能的异常及其对泪膜的影响[J]. 山东大学学报 (医学版), 2024, 62(6): 65-70.
[5]	姜任东,赵建莉,时超,贺业腾,袁振. 加速康复外科理念下全膝关节置换治疗类风湿关节炎与骨关节炎患者的临床疗效[J]. 山东大学学报 (医学版), 2024, 62(10): 62-67.
[6]	王蕾,向淇,刘学伍. 伴系统性硬化症、类风湿关节炎的副肿瘤神经综合征1例[J]. 山东大学学报 (医学版), 2023, 61(7): 118-120.
[7]	尚阳丽,钟光彩,李世洁,孙洺山,陈春燕. 31例获得性凝血因子缺乏症的回顾性分析[J]. 山东大学学报 (医学版), 2023, 61(5): 25-30.
[8]	徐洪波,胡仁琴,田茂强,冉潇,陈艳. PIK3CD基因杂合突变所致新表型——系统性红斑狼疮[J]. 山东大学学报 (医学版), 2023, 61(1): 113-117.
[9]	成晅,杨帆,潘正论. 系统性红斑狼疮、抗磷脂抗体综合征伴颅内静脉窦血栓形成1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(6): 70-74.
[10]	孔林笑语,孙书珍,余丽春,贾梦文. 188例儿童系统性红斑狼疮5年生存率及预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 69-76.
[11]	杨岫岩,张建瑜. 从风湿免疫角度谈生殖免疫的一些思路[J]. 山东大学学报 (医学版), 2021, 59(8): 20-23.
[12]	赵冰清,高选,李江夏. 基于辅助生殖人群的复发性流产夫妇染色体核型回顾性分析[J]. 山东大学学报 (医学版), 2021, 59(7): 26-31.
[13]	王百惠,宋艳君,张帅庆,左秀丽,王青,张爱军,李如源. 以腹泻为首发症状的淀粉样变3例及文献复习[J]. 山东大学学报 (医学版), 2020, 58(5): 93-97.
[14]	冯洒然,刘倩,王焱,李红,毕可红,朱传升. 系统性红斑狼疮伴发肝脾γδT细胞淋巴瘤1例并文献复习[J]. 山东大学学报 (医学版), 2018, 56(6): 87-90.
[15]	张好. 系统性红斑狼疮合并狼疮脑病、重症自身免疫性胰腺炎1例[J]. 山东大学学报 (医学版), 2018, 56(2): 93-94.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed